NVIDIA Chairman Says Jensen Huang Will Not Return as Fed Minutes Signal Rate Hikes

Stock News48 minutes ago

Tencent Holdings (00700) reported third-quarter profit attributable to shareholders of 63.612 billion yuan, up 0.8% year-on-year, while WorkBuddy topped China's AI application usage rankings.

Tencent Holdings released its results for the three months ended September 30, 2026, recording revenue of 207.336 billion yuan (RMB, same unit below), up 8% year-on-year; profit attributable to equity holders of the company was 63.612 billion yuan, up 0.8% year-on-year; basic earnings per share were 7.059 yuan.

For the nine months ended September 30, 2026, revenue reached 608.579 billion yuan, up 9% year-on-year; profit attributable to equity holders of the company was 177.727 billion yuan, up 7% year-on-year; basic earnings per share were 19.697 yuan.

Measured by large language model token consumption, WorkBuddy has become China's most-used AI product, with more than ten million daily users collectively consuming over 100 trillion tokens, while enterprise customers are also growing rapidly.

On Tencent's third-quarter 2026 earnings call, addressing the impact of computing-power-related restrictions on Tencent's AI business, Tencent President Liu Chiping said that both leased and self-built computing power face constraints, model training will inevitably be affected, and in the short term it may take longer to launch the next version of the Hunyuan model.

Liu Chiping noted that during model training and inference, Tencent found that computing efficiency is in fact improving rapidly year by year, and the approach previously adopted in Hunyuan 4 model training was already highly efficient.

Over the long term, the domestic supply chain will gradually participate in the model inference stage, and given the very rapid pace of domestic industry development, this localization process is expected to accelerate further.

Tencent Chairman and CEO Ma Huateng said, "We have made a series of important progress at the model and application levels, accelerating Tencent's evolution toward a new AI era."

Market outlook

The three major US stock indices closed mixed, with the "Magnificent Seven" tech giants modestly higher overall.

Overnight, the Dow Jones Industrial Average fell 561.25 points to close at 50,198.17, down 1.11%; the S&P 500 fell 16.9 points to close at 7,323.63, down 0.23%; the Nasdaq Composite rose 101.5 points to close at 24,429.88, up 0.42%.

The "Magnificent Seven" moved modestly higher overall with further divergence internally: Amazon rose 3.82%, Tesla rose 0.95%, Alphabet Class A rose 0.80%, Microsoft rose 0.40%, Apple rose 0.15%; Meta fell 0.40%, and NVIDIA (NASDAQ: NVDA) fell 2.89%.

Energy stocks also declined, with Exxon Mobil down 3.97%, Chevron down 3.95%, and ConocoPhillips down 3.64%.

Chinese concept stocks retreated broadly, with the Nasdaq Golden Dragon China Index down 1.35% at 5,291.64, as e-commerce and new energy vehicle makers generally weakened.

The Hang Seng Index ADR declined, calculated proportionally at 23,054.66, down 240.09 points or 1.03% from the Hong Kong close.

On the New York Mercantile Exchange, the front-month continuous WTI crude oil futures contract fell $3.27 to $82.74 per barrel, down 3.80%. COMEX front-month continuous gold futures fell $136.00, or 3.52%, to $3,728.2 per ounce.

Key developments to watch

NVIDIA (NASDAQ: NVDA) board chairman said Jensen Huang will not return.

The board chairman of NVIDIA (NASDAQ: NVDA) said at an employee meeting that Jensen Huang will not return. The NVIDIA board is reported to have approached Arm CEO Rene Haas during its search for a CEO.

Fed minutes signal rate hikes as Daly stresses the importance of cautious tightening.

San Francisco Fed President Mary Daly said the Federal Reserve still needs to raise interest rates further, but should adopt a cautious, gradual approach to monetary tightening while assessing changes in the US economic situation.

Speaking via video link on Wednesday (November 18) at a conference hosted by the St. Louis Fed, Daly said, "We must raise rates further to ensure we can be sufficiently confident that inflation is on a path of gradually returning to 2%."

Fed Governor Waller said that without signaling a January rate hike, a 50 basis point hike should come in December; the Fed will need to use other means to signal a more aggressive response to inflation; to reduce inflation, the Fed may have to take more measures than reversing last year's rate cuts.

China continued to sharply reduce its US Treasury holdings, while Belgium and Canada added to theirs.

Foreign holdings of US Treasuries posted their largest decline in six months in September, mainly due to reduced holdings by China and France.

Data released by the US Treasury Department on Wednesday showed that total overseas holdings fell by $75.5 billion from August to the lowest level in a year at $9.24 trillion. Foreign holdings data includes valuation changes as well as net purchases and sales.

The US Treasury index fell sharply by 2.2% in September, when the Fed began a new round of rate hikes to curb inflation.

China, the third-largest holder of US Treasuries, reduced its holdings by nearly $27 billion in September, bringing the total to about $564 billion. Some analysts believe China may have traded some US securities through other countries such as Canada.

Victory Giant Technology (02476) obtained a commitment letter for a special loan for share buybacks from a financial institution.

Victory Giant Technology (02476) announced that on November 17, 2026, the company obtained a "Loan Commitment Letter" issued by the Huizhou Branch of Industrial and Commercial Bank of China, committing to provide a special loan facility for the company's current share buyback, with a loan amount not exceeding 270 million yuan, and not exceeding 90% of the upper limit of the share buyback amount approved by the listed company's authorized body.

Zhongji Innolight's order visibility extends to 2028, advancing on dual tracks of high-speed optical modules and next-generation technologies.

Reporters learned from Zhongji Innolight that the company, leveraging advantages in high-end product iteration, large-scale delivery, and global capacity coordination, has achieved rapid revenue growth, with order visibility further extended to 2028.

In next-generation products, Zhongji Innolight continues to advance 3.2T optical module development and is laying out technology routes including NPO, XPO, CPO, and OCS, expanding optical interconnect solutions for AI data center scale-out and scale-up scenarios. It is understood that demand for products such as NPO and XPO is expected to gradually be released in the second half of 2027, providing new momentum for subsequent business growth.

Shanghai Pharmaceuticals (02607): ANDA for eltrombopag olamine tablets received US FDA approval for marketing.

Eltrombopag olamine tablets are mainly used for chronic immune (idiopathic) thrombocytopenia and severe aplastic anemia, originally developed by Novartis and launched in the US in 2008. In September 2025, Changzhou Pharmaceutical Factory submitted an ANDA application for the drug to the US FDA and recently received approval for marketing. As of the date of this announcement, the company has invested approximately RMB 9.8777 million in R&D for the drug. The ANDA approval from the US FDA for eltrombopag olamine tablets by Changzhou Pharmaceutical Factory Co., Ltd. is positive for the company's further expansion into overseas markets and accumulates valuable experience.

Yuegang'ao Intelligent Computing (01396) plans to repurchase up to HK$200 million of shares.

The board believes that the company's current share price does not fully reflect the company's intrinsic value and long-term development prospects, and that conducting the proposed share repurchase under current conditions can demonstrate the company's confidence in its business and development prospects, enhance share value, and improve shareholder returns, in line with the overall best interests of the company and shareholders. The proposed share repurchase will be funded from the company's internal resources.

Recbio-B (02179) plans to issue approximately 70.1393 million new H shares to Hong Kong Huyou Health Co., Ltd. at a premium of about 28.21%, raising net proceeds of about HK$344.5 million.

The net proceeds from the subscription are about HK$344.5 million, with about 30% for pre-launch preparation and commercial production layout of the recombinant shingles vaccine REC610; 30% for R&D activities and industrialization construction of the nine-valent HPV vaccine REC603; 20% for supplementing working capital; and 20% for repaying principal and interest owed to financial institutions that are not shareholders of the company.

Pony.ai-W (02026) third-quarter revenue rose 75.2% year-on-year to $44.6 million, with autonomous driving mobility service revenue surging 165%.

According to Zhitong Finance APP, Pony.ai-W (02026) announced its unaudited financial results for the third quarter ended September 30, 2026 (prepared under US GAAP). Third-quarter total revenue was $44.6 million (RMB 298.8 million), up 75.2% year-on-year, mainly driven by strong growth in autonomous driving mobility service and autonomous trucking service revenue.

Johnson Electric Holdings (00179) released interim results, with profit attributable to shareholders of $55.16 million, down 58.6% year-on-year.

Johnson Electric experienced a difficult first half of the 2026/27 fiscal year. Although revenue grew slightly, the considerable exchange gains recorded in the same period last year did not recur this period, and combined with intense price competition, input cost inflation, and operational challenges, the group's profit fell significantly during the period.

Stock in focus

GenScript Biotech (01548): the company is benefiting from AIDD wet-lab outsourcing demand.

AI pharmaceutical companies are becoming a new customer source for the CXO industry. GenScript previously disclosed actual business progress in AI-related services. Taking a single R&D base of a global top-20 pharmaceutical company as an example, GenScript's related service revenue from this customer expanded to five times the year-earlier level in the first half of 2026, with the share of AIDD S2D (sequence-to-data) service revenue rising from 23% to 64%.

Huatai Securities recently noted that the company held its 2026 Investor Day on October 30, sharing views on industry opportunities brought by AIDD, technology platform development, business layout, and long-term growth strategy.

As AI accelerates molecular design and candidate generation, experimental validation and data generation are becoming bottleneck links and important points of value release; GenScript, as a global leader in the life sciences industry, is benefiting from AIDD wet-lab outsourcing demand.

The company is bullish on AIDD driving strong growth in its life sciences business while other businesses develop in an orderly manner.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment